Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing a pipeline of therapies aimed at two major neurological challenges: multiple sclerosis (MS) and the acute effects of alcohol intoxication. The company’s efforts target conditions that affect hundreds of millions of people worldwide, where existing treatments often fall short.
MS is one of the most common debilitating neurological diseases in young adults, with an estimated 2.9 million people living with the disease globally, including about one million in the United States. Typically diagnosed between ages 20 and 50, MS affects females at roughly twice the rate of males. Quantum BioPharma’s lead MS candidate, Lucid-MS, is a patented new chemical entity that takes a fundamentally different approach from existing therapies. The company is supporting Lucid-MS’s Phase 2 development through an ongoing imaging collaboration with Massachusetts General Hospital, which aims to better understand the drug’s mechanism and effects.
In addition to MS, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses the cognitive and physiological impairments associated with alcohol consumption, which affect millions of people regularly.
The company’s dual-pronged strategy highlights its focus on neurological disorders with high unmet medical need. For more information on the terms and disclaimers related to this content, visit IBN.fm/Disclaimer. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Forward-looking statements in this article involve risks and uncertainties, including those described under "Risk Factors" in the Company's filings with the SEC. Readers should not place undue reliance on these statements, which are based on information available as of the date hereof. The Company undertakes no duty to update this information unless required by law.
